NasdaqGM:CERS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$960.3m

Last Updated

2021/06/23 12:44 UTC

Data Sources

Company Financials +

Executive Summary

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. More Details


Snowflake Analysis

Adequate balance sheet with concerning outlook.


Similar Companies

Share Price & News

How has Cerus's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CERS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: CERS's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

-2.3%

CERS

2.7%

US Medical Equipment

-0.1%

US Market


1 Year Return

-15.8%

CERS

35.7%

US Medical Equipment

39.0%

US Market

Return vs Industry: CERS underperformed the US Medical Equipment industry which returned 35.7% over the past year.

Return vs Market: CERS underperformed the US Market which returned 39% over the past year.


Shareholder returns

CERSIndustryMarket
7 Day-2.3%2.7%-0.1%
30 Day-4.4%3.9%2.6%
90 Day-1.2%10.9%8.0%
1 Year-15.8%-15.8%36.7%35.7%41.2%39.0%
3 Year-15.3%-15.3%69.2%65.3%62.4%52.3%
5 Year-10.2%-10.2%161.1%142.3%132.3%106.2%

Long-Term Price Volatility Vs. Market

How volatile is Cerus's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cerus undervalued compared to its fair value and its price relative to the market?

10.34x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CERS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CERS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CERS is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: CERS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CERS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CERS is overvalued based on its PB Ratio (10.3x) compared to the US Medical Equipment industry average (4.7x).


Future Growth

How is Cerus forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

4.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CERS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CERS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CERS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CERS's revenue (19.9% per year) is forecast to grow faster than the US market (9.4% per year).

High Growth Revenue: CERS's revenue (19.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CERS's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Cerus performed over the past 5 years?

-0.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CERS is currently unprofitable.

Growing Profit Margin: CERS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CERS is unprofitable, and losses have increased over the past 5 years at a rate of 0.6% per year.

Accelerating Growth: Unable to compare CERS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CERS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (11.1%).


Return on Equity

High ROE: CERS has a negative Return on Equity (-65.69%), as it is currently unprofitable.


Financial Health

How is Cerus's financial position?


Financial Position Analysis

Short Term Liabilities: CERS's short term assets ($181.3M) exceed its short term liabilities ($54.8M).

Long Term Liabilities: CERS's short term assets ($181.3M) exceed its long term liabilities ($73.2M).


Debt to Equity History and Analysis

Debt Level: CERS's debt to equity ratio (69.7%) is considered high.

Reducing Debt: CERS's debt to equity ratio has increased from 23.8% to 69.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CERS has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: CERS has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 0.7% each year.


Dividend

What is Cerus's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CERS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CERS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CERS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CERS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CERS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.4yrs

Average management tenure


CEO

Obi Greenman (53 yo)

10.17yrs

Tenure

US$4,520,750

Compensation

Mr. William M. Greenman, also known as Obi, has been the Chief Executive Officer and President of Cerus Corporation since April 2011. Mr. Greenman served as the Chief Business Officer of Cerus Corporation ...


CEO Compensation Analysis

Compensation vs Market: Obi's total compensation ($USD4.52M) is above average for companies of similar size in the US market ($USD2.34M).

Compensation vs Earnings: Obi's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: CERS's management team is seasoned and experienced (8.4 years average tenure).


Board Members

Experienced Board: CERS's board of directors are considered experienced (7.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.4%.


Top Shareholders

Company Information

Cerus Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cerus Corporation
  • Ticker: CERS
  • Exchange: NasdaqGM
  • Founded: 1991
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$960.272m
  • Shares outstanding: 171.17m
  • Website: https://www.cerus.com

Number of Employees


Location

  • Cerus Corporation
  • 1220 Concord Avenue
  • Concord
  • California
  • 94520
  • United States

Listings


Biography

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for cont...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/23 12:44
End of Day Share Price2021/06/22 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.